Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReVeRA-301 etripamil nasal spray in atrial fibrillation
NL-OMON61411Phase 3Recruiting
- Sponsor
- Milestone Pharmaceuticals
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing etripamil nasal spray with placebo (2 arms). Primary endpoint: Maximum reduction in ventricular rate within 30 minutes. Started Sep 2026; status: recruiting.
02
Drugs
etripamil
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON61411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61411.